Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis.

TY - JOUR

T1 - Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis.

AU - Feuerhahn, Julia

AU - Blome, Christine

AU - Radtke, Marc

AU - Augustin, Matthias

PY - 2012

Y1 - 2012

N2 - Empirical evidence of the efficacy of drugs and therapeutic procedures becomes more important in industrial countries. The assessment of patient benefit from the patient's perspective is of particular relevance. The Patient Benefit Index (PBI) for skin diseases is a validated instrument to assess patient-relevant benefit in patients with skin diseases. So far, no instrument for the assessment of patient-relevant needs and benefits in patients with psoriasis has been published. Objective of the study was the validation of an instrument to assess patient benefit in psoriasis treatment. Patient-relevant treatment needs and benefits in psoriasis patients were recorded with the PBI questionnaire in two studies conducted in 2007. Treatment goals and benefits were used to calculate an importance-weighted PBI. Data of n = 2,009 patients in the cross-sectional study and n = 93 patients in the longitudinal study were used to test validity, feasibility and reliability of the PBI. The PBI was feasible with a rate of missing values ?1.5 % in PNQ and ?2.0 % in PBQ. The subscales of the PBI were internally consistent (Cronbach's alpha = 0.68-0.87). The PBI showed convergent validity regarding the quality of life, psoriasis area and severity index, and two single questions on treatment benefit used in the longitudinal study. The PBI is a suitable instrument for the assessment of patient-reported benefit in the treatment of psoriasis.

AB - Empirical evidence of the efficacy of drugs and therapeutic procedures becomes more important in industrial countries. The assessment of patient benefit from the patient's perspective is of particular relevance. The Patient Benefit Index (PBI) for skin diseases is a validated instrument to assess patient-relevant benefit in patients with skin diseases. So far, no instrument for the assessment of patient-relevant needs and benefits in patients with psoriasis has been published. Objective of the study was the validation of an instrument to assess patient benefit in psoriasis treatment. Patient-relevant treatment needs and benefits in psoriasis patients were recorded with the PBI questionnaire in two studies conducted in 2007. Treatment goals and benefits were used to calculate an importance-weighted PBI. Data of n = 2,009 patients in the cross-sectional study and n = 93 patients in the longitudinal study were used to test validity, feasibility and reliability of the PBI. The PBI was feasible with a rate of missing values ?1.5 % in PNQ and ?2.0 % in PBQ. The subscales of the PBI were internally consistent (Cronbach's alpha = 0.68-0.87). The PBI showed convergent validity regarding the quality of life, psoriasis area and severity index, and two single questions on treatment benefit used in the longitudinal study. The PBI is a suitable instrument for the assessment of patient-reported benefit in the treatment of psoriasis.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Adolescent

KW - Questionnaires

KW - Cross-Sectional Studies

KW - Psoriasis/therapy

KW - Outcome Assessment (Health Care)

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Aged, 80 and over

KW - Adolescent

KW - Questionnaires

KW - Cross-Sectional Studies

KW - Psoriasis/therapy

KW - Outcome Assessment (Health Care)

M3 - SCORING: Journal article

VL - 304

SP - 433

EP - 441

JO - ARCH DERMATOL RES

JF - ARCH DERMATOL RES

SN - 0340-3696

IS - 6

M1 - 6

ER -